0001554795-18-000318.txt : 20181107 0001554795-18-000318.hdr.sgml : 20181107 20181106180155 ACCESSION NUMBER: 0001554795-18-000318 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 23 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181107 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINOVATION PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001118072 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 870458170 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30991 FILM NUMBER: 181164182 BUSINESS ADDRESS: STREET 1: 2157 S. LINCOLN ST CITY: SALT LAKE CITY STATE: UT ZIP: 84106 BUSINESS PHONE: 8013232395 MAIL ADDRESS: STREET 1: 2157 S. LINCOLN ST CITY: SALT LAKE CITY STATE: UT ZIP: 84106 10-Q 1 skin1029form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission file number: 000-30991

 

SKINOVATION PHARMACEUTICAL INCORPORATED

(Exact name of registrant as specified in its charter)

Wyoming

(State or other jurisdiction of incorporation or organization)

87-0458170

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip Code)

(801) 323-2395

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐ The registrant does not have a Web site.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Non-accelerated filer ☐

Emerging growth company ☑

Accelerated filer ☐

Smaller reporting company ☑

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☑ No ☐

 

The number of shares outstanding of the registrant’s common stock as of November 1, 2018 was 708,000.

 
 

TABLE OF CONTENTS

 

  PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements (unaudited) 2
Condensed Balance Sheets 3
  Condensed Statements of Operations 4
  Condensed Statements of Cash Flows 5
  Notes to the Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 7
Item 3. Quantitative and Qualitative Disclosures about Market Risk 9
Item 4. Controls and Procedures 9
     
  PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 10
Item 1a. Risk Factors Information 10
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 10
Item 3. Defaults Upon Senior Securities 10
Item 4. Mine Safety Disclosures 10
Item 5. Other Information 10
Item 6. Exhibits 10
Signatures 11

 

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

 

 

 

SKINOVATION PHARMACEUTICAL INCORPORATED

 

Condensed Financial Statements

 

September 30, 2018

 

(Unaudited)

 

 2 

 

Skinovation Pharmaceutical Incorporated

Condensed Balance Sheets

(Unaudited)

       
  

SEPT 30,

2018

 

DEC 31,

2017

       
ASSETS          
Current Assets          
Cash  $147   $547 
Total Current Assets   147    547 
Total Assets  $147   $547 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current Liabilities          
Accounts payable  $12,800   $6,600 
Notes payable   190,621    186,421 
Accrued interest   74,734    63,396 
Total Current Liabilities   278,155    256,417 
Total Liabilities   278,155    256,417 
Stockholders' Deficit          
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding   —      —   
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding   708    708 
Additional paid in capital   25,148    25,148 
Accumulated deficit   (303,864)   (281,726)
Total Stockholders' Deficit   (278,008)   (255,870)
Total Liabilities and Stockholders' Deficit  $147   $547 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 3 

 

Skinovation Pharmaceutical Incorporated

Condensed Statements of Operations

(Unaudited)

             
   FOR THE
THREE MONTHS ENDED
SEPT 30, 2018		  FOR THE
THREE MONTHS ENDED
SEPT 30, 2017		  FOR THE
NINE
MONTHS ENDED
SEPT 30, 2018		  FOR THE
NINE
MONTHS ENDED
SEPT 30, 2018
             
REVENUES  $—     $—     $—     $—   
             
EXPENSES                    
General and administrative   2,615    2,605    10,800    10,730 
TOTAL EXPENSES   2,615    2,605    10,800    10,730 
                     
INCOME (LOSS) BEFORE OTHER EXPENSE   (2,615)   (2,605)   (10,800)   (10,730)
                     
OTHER INCOME (EXPENSE)                    
Interest expense   (3,812)   (3,556)   (11,338)   (10,496)
Total other income (expense)   (3,812)   (3,556)   (11,338)   (10,496)
                     
INCOME (LOSS) BEFORE INCOME TAXES   (6,427)   (6,161)   (22,138)   (21,226)
                     
INCOME TAXES   —      —      —      —   
                     
NET INCOME (LOSS)  $(6,427)  $(6,161)  $(22,138)  $(21,226)
                     
Basic and diluted net income (loss) per share  $(0.01)  $(0.01)  $(0.03)  $(0.03)
                     
Weighted average shares outstanding   708,000    708,000    708,000    708,000 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 4 

 

Skinovation Pharmaceutical Incorporated

Condensed Statements of Cash Flows

(Unaudited)

       
  

FOR THE

NINE MONTHS

ENDED

SEPT 30,

2018

 

FOR THE

NINE MONTHS

ENDED

SEPT 30,

2017

       
Cash Flows from Operating Activities          
Net income (loss)  $(22,138)  $(21,226)
Adjustments to reconcile net loss to cash used by operating activities:          
Changes in assets and liabilities:          
Increase in accounts payable   6,200    5,100 
Increase in accrued interest   11,338    10,496 
Net cash used by operating activities   (4,600)   (5,630)
           
Cash Flows from Investing Activities          
Net cash used by investing activities   —      —   
           
Cash Flows from Financing Activities          
Proceeds from notes payable   4,200    6,000 
Net cash provided by financing activities   4,200    6,000 
           
Increase (decrease) in cash   (400)   370 
           
Cash and cash equivalents at beginning of year   547    277 
           
Cash and cash equivalents at end of year  $147   $647 
           
Supplemental Cash Flow Information:          
Cash paid for interest  $—     $—   
Cash paid for income taxes  $—     $—   

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 5 

 

Skinovation Pharmaceutical Incorporated

Notes to the Unaudited Condensed Financial Statements

September 30, 2018

 

 

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

 

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2018 and for all periods presented have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2017 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2018 are not necessarily indicative of the operating results for the full year ended December 31, 2018.

 

 

NOTE 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

 

 

NOTE 3 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

  

 6 

 

 

In this report references to “Skinovation,” “we,” “us,” and “our” refer to Skinovation Pharmaceutical Incorporated.

 

FORWARD LOOKING STATEMENTS

 

The U. S. Securities and Exchange Commission (“SEC”) encourages reporting companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “expect,” “believe,” “intend,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Executive Overview

 

We have not recorded revenues and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

 

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

 

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

 

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

 

Liquidity and Capital Resources

 

We have not recorded revenues from operations during 2018 and 2017 and have not established an ongoing source of revenue sufficient to cover our operating costs. We expect to rely upon third parties to pay for our operating expenses. At September 30, 2018 we had cash of $147 compared to $547 cash at December 31, 2017. Our total liabilities increased to $278,155 at September 30, 2018 from $256,417 at December 31, 2017. The increase in total liabilities is primarily due to increases in accounts payable for professional fees, notes payable and accrued interest.

 

We intend to obtain capital from management, significant stockholders and third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

 

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans provided by management, significant stockholders or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

 

 7 

 

Results of Operations

 

We did not record revenues in 2018 or 2017. General and administrative expense for the 2018 third quarter was $2,615 compared to $2,605 for the 2017 third quarter. General and administrative expense increased to $10,800 for the 2018 nine month period compared to $10,730 for the 2017 nine month period.

 

Total other expense representing interest expense on notes payable increased to $3,812 for the 2018 third quarter compared to $3,556 for the 2017 third quarter and increased to $11,338 for the 2018 nine month period compared to $10,496 for the 2017 nine month period.

 

Our net loss increased to $6,427 for the 2018 third quarter compared to $6,161 for the 2017 third quarter and net loss increased to $22,138 for the 2018 nine month period compared to $21,226 for the 2017 nine month period. Management expects net losses to continue until we acquire or merge with a business opportunity.

 

Commitments and Obligations

 

At September 30, 2018 we had outstanding notes payable totaling $190,621. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand. For the 2018 nine month period we recorded interest expense of $11,338 for the notes payable and recorded total accrued interest at September 30, 2018 of $74,734.

 

During the 2018 nine month period we incurred $6,200 in accounts payable for consulting services and professional services provided by, or paid for by, third parties.

 

Two lenders represent in excess of 95% of the Company’s accounts payable and notes payable at September 30, 2018.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Emerging Growth Company

 

We qualify as an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements

 

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

 8 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were not effective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

 

Changes to Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

 9 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

 

 

ITEM 1A.  RISK FACTORS

 

A smaller reporting company is not required to provide the information required by this Item.

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

ITEM 5. OTHER INFORMATION

 

None.

 

 

ITEM 6. EXHIBITS

 

Part I Exhibits

No. Description
31.1 Principal Executive Officer Certification
31.2 Principal Financial Officer Certification
32.1 Section 1350 Certification

 

Part II Exhibits

No.    Description
3(i)

Wyoming Articles of Domestication, filed November 23, 2016 (Incorporated by reference to exhibit 3(i).2 of Form 10-K, filed March 20, 2017)

3(ii)

Bylaws of Skinovation (Incorporated by reference to exhibit 3(ii) of Form 10-K, filed March 20, 2017)

101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Label Linkbase Document
101.PRE XBRL Taxonomy Presentation Linkbase Document

 

 10 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

Date: November 6, 2018

SKINOVATION PHARMACEUTICAL INCORPORATED

 

 

By:   /s/ Hugo Rodier

Hugo Rodier

President and Director

Principal Financial Officer

 

 

11

 EX-31.1 2 skin1029form10qexh31_1.htm EXHIBIT 31.1

Exhibit 31.1

 

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

 

I, Hugo Rodier, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Skinovation Pharmaceutical Incorporated;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: November 6, 2018

 

 

/s/ Hugo Rodier

Hugo Rodier

Principal Executive Officer

 EX-31.2 3 skin1029form10qexh31_2.htm EXHIBIT 31.2

Exhibit 31.2

 

PRINCIPAL FINANCIAL OFFICER CERTIFICATION

 

I, Hugo Rodier, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Skinovation Pharmaceutical Incorporated;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: November 6, 2018

 

 

/s/ Hugo Rodier

Hugo Rodier

Principal Financial Officer

 EX-32.1 4 skin1029form10qexh32_1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

SKINOVATION PHARMACEUTICAL INCORPORATED

 

CERTIFICATION OF PERIODIC REPORT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

18 U.S.C. Section 1350

 

The undersigned executive officer of Skinovation Pharmaceutical Incorporated certifies pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

a.the quarterly report on Form 10-Q of Skinovation Pharmaceutical Incorporated for the quarter ended September 30, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

b.the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Skinovation Pharmaceutical Incorporated.

 

 

 

 

Date: November 6, 2018

 

 

/s/ Hugo Rodier

Hugo Rodier

Principal Executive Officer

Principal Financial Officer

 EX-101.INS 5 skin-20180930.xml XBRL INSTANCE FILE 0001118072 2018-01-01 2018-09-30 0001118072 2018-11-01 0001118072 2018-09-30 0001118072 2017-12-31 0001118072 2018-07-01 2018-09-30 0001118072 2017-07-01 2017-09-30 0001118072 2017-01-01 2017-09-30 0001118072 2016-12-31 0001118072 2017-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SKINOVATION PHARMACEUTICAL INC 0001118072 10-Q 2018-09-30 false --12-31 Yes Non-accelerated Filer Q3 2018 708000 0.001 0.001 25000000 25000000 0 0 0 0 0.001 0.001 50000000 50000000 708000 708000 708000 708000 <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 1 &#8211; CONDENSED FINANCIAL STATEMENTS</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2018 and for all periods presented have been made.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s December 31, 2017 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2018 are not necessarily indicative of the operating results for the full year ended December 31, 2018.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 3 &#8211; SUBSEQUENT EVENTS</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 2 &#8211; GOING CONCERN</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management&#8217;s plan to acquire or merge with other operating companies.</p> 147 547 147 547 147 547 277 647 147 547 -278008 -255870 -303864 -281726 25148 25148 708 708 278155 256417 278155 256417 74734 63396 190621 186421 12800 6600 708000 708000 708000 708000 -4600 -5630 11338 10496 -6200 -5100 4200 6000 4200 6000 -400 370 true false true 10800 2615 2605 10730 10800 2615 2605 10730 -10800 -2615 -2605 -10730 -11338 -3812 -3556 -10496 11338 3812 3556 10496 -22138 -6427 -6161 -21226 -22138 -6427 -6161 -21226 -0.03 -0.01 -0.01 -0.03 EX-101.SCH 6 skin-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Condensed Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 skin-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 skin-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 skin-20180930_lab.xml XBRL LABEL FILE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Is Entity Emerging Growth Company? Elected Not To Use the Extended Transition Period Entity Filer Category Entity Small Business Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total Current Assets Total Assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable Notes payable Accrued interest Total Current Liabilities Total Liabilities Stockholders' Deficit Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding Additional paid in capital Accumulated deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Preferred stock, par value Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] REVENUES EXPENSES General and administrative Total Expenses INCOME (LOSS) BEFORE OTHER EXPENSE OTHER INCOME (EXPENSE) Interest expense Total other income (expense) INCOME (LOSS) BEFORE INCOME TAXES INCOME TAXES NET INCOME (LOSS) Basic and diluted net income (loss) per share Weighted average shares outstanding Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net income (loss) Adjustments to reconcile net loss to cash used by operating activities: Changes in assets and liabilities: Increase in accounts payable Increase in accrued interest Net cash used by operating activities Cash Flows from Investing Activities Net cash used by investing activities Cash Flows from Financing Activities Proceeds from notes payable Net cash provided by financing activities Increase (decrease) in cash Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Supplemental Cash Flow Information: Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Condensed Financial Statements Going Concern Subsequent Events [Abstract] Subsequent Events Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Other Operating Income (Expense), Net Income (Loss) from Continuing Operations before Income Taxes, Domestic Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) EX-101.PRE 10 skin-20180930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 01, 2018
Document And Entity Information    
Entity Registrant Name SKINOVATION PHARMACEUTICAL INC  
Entity Central Index Key 0001118072  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity's Reporting Status Current? Yes  
Is Entity Emerging Growth Company? true  
Elected Not To Use the Extended Transition Period false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Common Stock, Shares Outstanding   708,000
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2018  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash $ 147 $ 547
Total Current Assets 147 547
Total Assets 147 547
Current Liabilities    
Accounts payable 12,800 6,600
Notes payable 190,621 186,421
Accrued interest 74,734 63,396
Total Current Liabilities 278,155 256,417
Total Liabilities 278,155 256,417
Stockholders' Deficit    
Preferred stock, $.001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $.001 par value; 50,000,000 shares authorized; 708,000 shares issued and outstanding 708 708
Additional paid in capital 25,148 25,148
Accumulated deficit (303,864) (281,726)
Total Stockholders' Deficit (278,008) (255,870)
Total Liabilities and Stockholders' Deficit $ 147 $ 547
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, authorized 25,000,000 25,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 50,000,000 50,000,000
Common stock, issued 708,000 708,000
Common stock, outstanding 708,000 708,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
REVENUES
EXPENSES        
General and administrative 2,615 2,605 10,800 10,730
Total Expenses 2,615 2,605 10,800 10,730
INCOME (LOSS) BEFORE OTHER EXPENSE (2,615) (2,605) (10,800) (10,730)
OTHER INCOME (EXPENSE)        
Interest expense (3,812) (3,556) (11,338) (10,496)
Total other income (expense) (3,812) (3,556) (11,338) (10,496)
INCOME (LOSS) BEFORE INCOME TAXES (6,427) (6,161) (22,138) (21,226)
INCOME TAXES
NET INCOME (LOSS) $ (6,427) $ (6,161) $ (22,138) $ (21,226)
Basic and diluted net income (loss) per share $ (0.01) $ (0.01) $ (0.03) $ (0.03)
Weighted average shares outstanding 708,000 708,000 708,000 708,000
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows from Operating Activities    
Net income (loss) $ (22,138) $ (21,226)
Changes in assets and liabilities:    
Increase in accounts payable 6,200 5,100
Increase in accrued interest 11,338 10,496
Net cash used by operating activities (4,600) (5,630)
Cash Flows from Investing Activities    
Net cash used by investing activities
Cash Flows from Financing Activities    
Proceeds from notes payable 4,200 6,000
Net cash provided by financing activities 4,200 6,000
Increase (decrease) in cash (400) 370
Cash and cash equivalents at beginning of year 547 277
Cash and cash equivalents at end of year 147 647
Supplemental Cash Flow Information:    
Cash paid for interest
Cash paid for income taxes
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Financial Statements
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Condensed Financial Statements

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

 

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended September 30, 2018 and for all periods presented have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2017 audited financial statements as reported in its Form 10-K. The results of operations for the period ended September 30, 2018 are not necessarily indicative of the operating results for the full year ended December 31, 2018.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 2 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

NOTE 3 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.
EXCEL 19 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 21 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 9 59 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://SKIN/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://SKIN/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://SKIN/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://SKIN/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://SKIN/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Condensed Financial Statements Sheet http://SKIN/role/FinancialStatements Condensed Financial Statements Notes 6 false false R7.htm 00000007 - Disclosure - Going Concern Sheet http://SKIN/role/GoingConcern Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Subsequent Events Sheet http://SKIN/role/SubsequentEvents Subsequent Events Notes 8 false false All Reports Book All Reports skin-20180930.xml skin-20180930.xsd skin-20180930_cal.xml skin-20180930_def.xml skin-20180930_lab.xml skin-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 25 0001554795-18-000318-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001554795-18-000318-xbrl.zip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end